Oculis Holding AG (NASDAQ:OCS) Sees Large Decline in Short Interest

Oculis Holding AG (NASDAQ:OCS) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totaling 490,094 shares, a decrease of 21.5% from the February 26th total of 623,971 shares. Based on an average daily volume of 521,482 shares, the short-interest ratio is currently 0.9 days. Approximately 0.8% of the shares of the company are short sold.

Wall Street Analyst Weigh In

A number of analysts have issued reports on OCS shares. Stifel Nicolaus raised their target price on Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. HC Wainwright upped their price target on Oculis from $42.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Needham & Company LLC lifted their price objective on Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. initiated coverage on Oculis in a report on Friday, December 19th. They issued an “overweight” rating and a $38.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Oculis currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.86.

Oculis Price Performance

Shares of OCS stock traded up $2.04 during trading hours on Tuesday, reaching $26.59. The stock had a trading volume of 306,792 shares, compared to its average volume of 368,640. The stock’s fifty day simple moving average is $27.43 and its 200 day simple moving average is $22.66. The firm has a market capitalization of $1.54 billion, a PE ratio of -11.71 and a beta of 0.29. Oculis has a 12 month low of $14.00 and a 12 month high of $30.68. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%.The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.14 million. On average, equities research analysts predict that Oculis will post -2.09 EPS for the current year.

Institutional Investors Weigh In On Oculis

A number of institutional investors and hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its stake in Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after buying an additional 1,000 shares during the period. Aventura Private Wealth LLC bought a new position in Oculis in the 4th quarter worth about $80,000. Millennium Management LLC purchased a new stake in shares of Oculis in the 4th quarter valued at about $312,000. Bosun Asset Management LLC bought a new stake in shares of Oculis during the 2nd quarter valued at about $378,000. Finally, Marshall Wace LLP bought a new stake in shares of Oculis during the 2nd quarter valued at about $393,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.